Gardner TA - Search Results

1

Future innovations in treating advanced prostate cancer.

Desai P, Jiménez JA, Kao C, Gardner TA. Desai P, et al. Among authors: gardner ta. Urol Clin North Am. 2006 May;33(2):247-72, viii. doi: 10.1016/j.ucl.2005.12.005. Urol Clin North Am. 2006. PMID: 16631463 Review.

2

Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.

Cheon J, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C, Chung LW. Cheon J, et al. Among authors: gardner ta. Cancer Gene Ther. 1997 Nov-Dec;4(6):359-65. Cancer Gene Ther. 1997. PMID: 9408606

3

Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.

Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Gotoh A, et al. Among authors: gardner ta. J Urol. 1998 Jul;160(1):220-9. J Urol. 1998. PMID: 9628654

4

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.

Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LW, Kao C. Shirakawa T, et al. Among authors: gardner ta. Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80. Cancer Gene Ther. 1998. PMID: 9824046

5

Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.

Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C. Shirakawa T, et al. Among authors: gardner ta. J Urol. 1999 Sep;162(3 Pt 1):949-54. doi: 10.1097/00005392-199909010-00096. J Urol. 1999. PMID: 10458414

6

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.

Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA. Koeneman KS, et al. Among authors: gardner ta. World J Urol. 2000 Apr;18(2):102-10. doi: 10.1007/s003450050181. World J Urol. 2000. PMID: 10854144 Clinical Trial.

7

p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model.

Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S, Wada Y, Hinata N, Fujisawa M, Hanioka K, Matsuo M, Kamidono S. Shirakawa T, et al. Among authors: gardner ta. J Gene Med. 2000 Nov-Dec;2(6):426-32. doi: 10.1002/1521-2254(200011/12)2:6<426::AID-JGM140>3.0.CO;2-2. J Gene Med. 2000. PMID: 11199263

8

A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.

Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW. Matsubara S, et al. Among authors: gardner ta. Cancer Res. 2001 Aug 15;61(16):6012-9. Cancer Res. 2001. PMID: 11507044

9

Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells.

Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Shirakawa T, et al. Among authors: gardner ta. Int J Cancer. 2001 Oct 15;94(2):282-9. doi: 10.1002/ijc.1453. Int J Cancer. 2001. PMID: 11668510 Free article.

10

Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer.

Zhang S, Gu J, Yang NS, Kao C, Gardner TA, Eble JN, Cheng L. Zhang S, et al. Among authors: gardner ta. Prostate. 2002 Jun 1;51(4):286-92. doi: 10.1002/pros.10081. Prostate. 2002. PMID: 11987157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page